NCT02280616View on ClinicalTrials.gov

Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2014

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

low dose budesonide tablet

1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily

DRUG

high dose budesonide tablet

2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily

DRUG

high dose budesonide suspension

placebo tablet twice daily AND 5ml \[0.4mg budesonide/ml\] suspension twice daily

DRUG

Placebo

placebo tablet twice daily AND 5ml placebo suspension twice daily

Trial Locations (1)

20249

Center for Digestive Diseases Eppendorf, Hamburg

Sponsors
All Listed Sponsors
lead

Dr. Falk Pharma GmbH

INDUSTRY